IRCT20200105046010N127 IRCT 2025-01-05 Zistdaru danesh Co. Bioequivalence study of the intravenous solution of Ferric carboxy maltose Bioequivalence study of the intravenous solution of Ferric carboxy maltose 50mg/ml (Ferririse)manufactured by Zistdaru Danesh versus originator brand (Ferinject) in healthy volunteers in the fasted condition 2024-12-21 anticipated 50 Complete https://irct.ir/trial/81084 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: People in the mentioned age group are invited to participate through the advertisement. People are then checked for health and eligible candidates are identified. Each candidate is assigned a number from 1 to 50. The rand function of Excel software was used for randomization. The first 25 no.s are considered as (first sequence: Zistdaru Danesh's medicine ) and the second 25 no.s (second sequence: originator brand recipient). The volunteers don't have any information about taking the test or brand drug, Blinding description: This study is a single-blinded clinical trial (volunteers). The label of Zistdaru Danesh and the original brand are removed from the vials by the executor and the coded label is installed on it. Candidates don't know about receiving the type of brand medicine or test. Bioequivalence This study is conducted on healthy volunteers.. Intervention 1: Intervention group 1: injection solution of ferric carboxy maltose 50 mg/ml manufactured by Vifor Pharma company as a reference. Intervention 2: Intervention group 2: injection solution of ferric carboxy maltose 50 mg/ml manufactured by Zistdaru Danesh company as a test. No - There is not a plan to make this available Justification or reason for not sharing IPD is These data are as secure between researchers and related industries.